Medtech developments over the Christmas period
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Floating medtechs go big or go home
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Ortho Clinical takes a haircut
Discount pricing and poor first day defies the recent trend for floating device makers.
The FDA gets aggressive with Covid-19 antibody tests
Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.
Roche takes on Abbott in Covid-19 antibody testing
Robust specificity data mark Roche’s serological test out as a major competitor.
Covid-19 antibody tests face a very specific problem
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Few groups have developed Covid-19 diagnostics – but this will change
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
